Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jacobson

Showing results (1181-1190 of 1,226) with videos related to

Pageof 123
Sort By:
Lancet (London, England)|August 1, 2014
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stanislas Pol, Ira M Jacobson, et al.
Journal of Medical Genetics|July 3, 2021
Whole-exome sequencing reveals a monogenic cause in 56% of individuals with laterality disorders and associated congenital heart defectsYoav Bolkier, Ortal Barel, Dina Marek-Yagel, et al.
JAMA|October 2, 2008
Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trialNina Marano, Brian D Plikaytis, Stacey W Martin, et al.
The Journal of Infectious Diseases|November 24, 1999
Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccineS Frey, R Dagan, Y Ashur, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Plos One|October 5, 2023
Assessing the associations between known genetic variants and substance use in people with HIV in the United StatesCameron B Haas, Kristina M Jordahl, Robin M Nance, et al.
Clinical and Vaccine Immunology : CVI|February 12, 2016
Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in HumansConrad P Quinn, Carol L Sabourin, Jarad M Schiffer, et al.
The Journal of Clinical Investigation|July 20, 2018
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollersRadwa Sharaf, Guinevere Q Lee, Xiaoming Sun, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infectionEric Lawitz, Alessandra Mangia, David Wyles, et al.
Journal of Hepatology|September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
Pageof 123

Showing results (1181-1190 of 1,226) with videos related to

Sort By:
Pageof 123
Lancet (London, England)|August 1, 2014
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stanislas Pol, Ira M Jacobson, et al.
Journal of Medical Genetics|July 3, 2021
Whole-exome sequencing reveals a monogenic cause in 56% of individuals with laterality disorders and associated congenital heart defectsYoav Bolkier, Ortal Barel, Dina Marek-Yagel, et al.
JAMA|October 2, 2008
Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trialNina Marano, Brian D Plikaytis, Stacey W Martin, et al.
The Journal of Infectious Diseases|November 24, 1999
Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccineS Frey, R Dagan, Y Ashur, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Plos One|October 5, 2023
Assessing the associations between known genetic variants and substance use in people with HIV in the United StatesCameron B Haas, Kristina M Jordahl, Robin M Nance, et al.
Clinical and Vaccine Immunology : CVI|February 12, 2016
Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in HumansConrad P Quinn, Carol L Sabourin, Jarad M Schiffer, et al.
The Journal of Clinical Investigation|July 20, 2018
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollersRadwa Sharaf, Guinevere Q Lee, Xiaoming Sun, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infectionEric Lawitz, Alessandra Mangia, David Wyles, et al.
Journal of Hepatology|September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
Pageof 123